Story perspectives

New Drug Combo Doubles Survival for Colorectal Cancer

5/30/2025

26 3

Summary

Story summary

A new drug combination for aggressive colorectal cancer has doubled patient survival time, as reported in The New England Journal of Medicine.
This treatment combines chemotherapy, cetuximab, and Pfizer's Braftovi, targeting the BRAF V600E mutation present in 10% of patients.
Patients on this regimen lived an average of 30 months, compared to 15 months with standard chemotherapy.
The FDA has granted fast-track approval for this as a first-line therapy.
The trial included over 600 patients, revealing no unexpected safety issues.

1 of 1

Story summary

A new drug combination for aggressive colorectal cancer has doubled patient survival time, as reported in The New England Journal of Medicine.
This treatment combines chemotherapy, cetuximab, and Pfizer's Braftovi, targeting the BRAF V600E mutation present in 10% of patients.
Patients on this regimen lived an average of 30 months, compared to 15 months with standard chemotherapy.
The FDA has granted fast-track approval for this as a first-line therapy.
The trial included over 600 patients, revealing no unexpected safety issues.